Darifenacin (hydrobromide)
Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].
Product Specifications
CAS Number
[133099-07-7]
Product Name Alternative
UK-88525 (hydrobromide)
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Akt; mAChR; p38 MAPK
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; PI3K/Akt/mTOR
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Darifenacin-hydrobromide.html
Purity
99.97
Solubility
DMSO : 33.33 mg/mL (ultrasonic)
Smiles
O=C(C(C1=CC=CC=C1)([C@@H]2CCN(CCC3=CC4=C(OCC4)C=C3)C2)C5=CC=CC=C5)N.Br
Molecular Formula
C28H31BrN2O2
Molecular Weight
507.46
Precautions
H315, H319, H335
References & Citations
+
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
ERK1; ERK2; mAChR3; MMP-1
Citation 01
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral mouse Rdh12 shRNA (UAS) - Lentiviral mouse Rdh12 shRNA (UAS, GFP) plasmid
